±è¿ëÀç ¸íÀÇ

³úÁ¹Áß ¿¹¹æºÎÅÍ Àç¹ß ¹æÁö, Ç÷°ü¼º Ä¡¸Å±îÁö! ³ú°Ç°­À» µ¹º¸´Â Àü¹®°¡

±è¿ëÀç ¸íÀÇ

  • ¼Ò ¼Ó
    °¡Å縯´ëÇб³ ÀºÆò¼º¸ðº´¿ø ½Å°æ°ú
  • Àü¹®ºÐ¾ß
    ³úÁ¹Áß, Ç÷°ü¼º Ä¡¸Å, µÎÅë, (³úÁúȯ ¿¹¹æÀ» À§ÇÑ)ÀÌ»óÁöÇ÷Áõ, °íÇ÷¾Ð, ´ç´¢º´ °ü¸®

³úÁ¹Áß Ä¡·áÀÇ ´ë°¡·Î Àß ¾Ë·ÁÁø ±è¿ëÀç ±³¼ö´Â ´ëÇѳúÁ¹ÁßÇÐȸ ȸÀåÀ» ¿ªÀÓÇϸç, »îÀÇ ÇູÀ» ÇÑ ¼ø°£¿¡ ¾Ñ¾Æ°¥ ¼ö ÀÖ´Â ³úÁ¹ÁßÀÇ ¿¹¹æ°ú Ä¡·á¸¦ À§ÇØ Çå½ÅÇØ ¿Ô´Ù.
±³À°, ¿¬±¸, Áø·á¿¡ ÃÖ¼±À» ´ÙÇϸç, ƯÈ÷ Àç¹ß¼º ³úÁ¹Áß°ú °°Àº ¹Ýº¹µÇ´Â ¾î·Á¿òÀ» °Þ°í Àִ ȯÀÚ¿Í °¡Á·µéÀÌ ±× ¾î·Á¿òÀ» ±Øº¹ÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ´Ù. ¶ÇÇÑ, Ä¡¸ÅÀÇ Áß¿äÇÑ ¿øÀÎ ÁúȯÀÎ ³úÇ÷°ü ¼Õ»óÀ» ÃÖ¼ÒÈ­Çϱâ À§ÇÑ ³ë·Â µîÀ¸·Î ȯÀÚµéÀÇ ³ú °Ç°­À» Áö۱â À§ÇØ ²ÙÁØÈ÷ Èû¾²°í ÀÖ´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • °¡Å縯´ëÇб³ Àǰú´ëÇÐ
  • °¡Å縯´ëÇб³ Àǰú´ëÇÐ ´ëÇпø ¹Ú»ç

ÁÖ¿ä°æ·Â

Work Experience
  • °¡Å縯´ëÇб³ Àǰú´ëÇÐ ½Å°æ°ú ±³¼ö
  • ÀÌÈ­¿©ÀÚ´ëÇб³ Àǰú´ëÇÐ ½Å°æ°ú ÁÖÀÓ±³¼ö

ÇÐȸȰµ¿

Academic activities
  • 2024 ~ 2025´ëÇѳúÁ¹ÁßÇÐȸ ȸÀå
  • 2018 ~ 2022´ëÇѽŰæÃÊÀ½ÆÄÇÐȸ ȸÀå
  • 2023 ~ 2026WFN ½Å°æÃÊÀ½ÆÄºÐ°ú ºÎȸÀå
  • 2022 ~ 2026´ëÇѳëÀνŰæ°úÇÐȸ ƯÀÓÀÌ»ç, ¿ÏÈ­ÀÇ·áÀ§¿øÀå
  • 2020 ~ 2026´ëÇÑÀÓ»ó³ëÀÎÀÇÇÐȸ ¿¬±¸ÀÌ»ç, ´ë¿ÜÇù·ÂÀÌ»ç
±Þ¼º±â ³úÁ¹Áß Áø·á½Ã½ºÅÛ ±¸ÃàÀ» À§ÇÑ Áöħ¼­
´ëÇ¥¼­Àû

±Þ¼º±â ³úÁ¹Áß Áø·á½Ã½ºÅÛ ±¸ÃàÀ» À§ÇÑ Áöħ¼­

  • ÀúÀÚ(±Û)±è¿ëÀç
  • ÃâÆÇ»çµµ¼­ÃâÆÇ Áø±âȹ
  • ¹ßÇàÀÏ2014 ³â 12¿ù
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 6°Ç
Á¦ ¸ñ ½Å°æÃÊÀ½ÆÄ
ÃâÆÇ»ç JPNC ¹ßÇàÀÏ 2021.12
Á¦ ¸ñ ³úÁ¹Áß
ÃâÆÇ»ç (ÁÖ)¹ü¹®¿¡µàÄÉÀÌ¼Ç ¹ßÇàÀÏ 2024.01
Á¦ ¸ñ Management of Dementia from the Preclinical Stage
ÃâÆÇ»ç Springer ¹ßÇàÀÏ 2025.03
Á¦ ¸ñ °£È£»ç¸¦ À§ÇÑ ³úÁ¹Áß °£È£½Ç¹« ¸Å´º¾ó
ÃâÆÇ»ç JPNC ¹ßÇàÀÏ 2024.02
Á¦ ¸ñ ³ëÀÎÀÇÇÐ
ÃâÆÇ»ç ´ÚÅͽººÏ ¹ßÇàÀÏ 2018
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke
¹ßÇ¥³âµµ 2020 ¹ßÇ¥Áö New England Journal of Medicine
Á¦ ¸ñ Interarm Systolic and Diastolic Blood Pressure Difference Is Diversely Associated With Cerebral Atherosclerosis in Noncardioembolic Stroke Patients
¹ßÇ¥³âµµ 2018 ¹ßÇ¥Áö American Journal of Hypertension
Á¦ ¸ñ Rivaroxaban vs Warfarin Sodium in the Ultra-Early Period After Atrial Fibrillation–Related Mild Ischemic Stroke
¹ßÇ¥³âµµ 2017 ¹ßÇ¥Áö JAMA Neurology
Á¦ ¸ñ Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial
¹ßÇ¥³âµµ 2018 ¹ßÇ¥Áö Lancet Neurology
Á¦ ¸ñ Low Plasma Proportion of Omega 3-Polyunsaturated Fatty Acids Predicts Poor Outcome in Acute Non-Cardiogenic Ischemic Stroke Patients
¹ßÇ¥³âµµ 2015 ¹ßÇ¥Áö Journal of Stroke
Á¦ ¸ñ Low-density-lipoprotein particle size predicts a poor outcome in patients with atherothrombotic stroke.
¹ßÇ¥³âµµ 2015 ¹ßÇ¥Áö Journal of clinical neurology
Á¦ ¸ñ Plasma phospholipid fatty acid composition in ischemic stroke: Importance of docosahexaenoic acid in the risk for intracranial atherosclerotic stenosis
¹ßÇ¥³âµµ 2012 ¹ßÇ¥Áö Atherosclerosis

¸íÀÇqna ¸íÀÇ QnA

Q °¡Àå °ü½É ÀÖ´Â ºÐ¾ß¿Í ¾÷ÀûÀÌ ÀÖ´Ù¸é ¾Ë·ÁÁÖ¼¼¿ä

³úÁ¹Áß ¿¹¹æÀ» À§ÇØ ÀÌ»óÁöÇ÷Áõ(¿µ±¹ ±Û¶ó½º°í¿ì ÀÇ´ë), ½Å°æ ÃÊÀ½ÆÄ(¹Ì±¹ ¿þÀÌÅ©Æ÷·¹½ºÆ® ÀÇ´ë), ½ÉÇ÷°ü Áúȯ(¹Ì±¹ ͏®Æ÷´Ï¾Æ ÁÖ¸³´ëÇÐ ¾î¹ÙÀÎ) µî ´Ù¾çÇÑ ºÐ¾ß¿¡¼­ ´ÙÇÐÁ¦Àû Á¢±ÙÀ» Áö¼ÓÀûÀ¸·Î À¯ÁöÇϰí, ¼¼°èÀûÀÎ ¿¬±¸ÀÚµé°ú ±³·ùÇÏ¸ç ¿¬±¸¸¦ ÁøÇàÇß½À´Ï´Ù. ¶ÇÇÑ, ³úÁ¹Áß ÁýÁß Ä¡·á½ÇÀ» JCI CCPC ±âÁØ¿¡ ¸ÂÃç ÀÎÁõÀ» ¹Þ°í ½Ã½ºÅÛÈ­ÇÏ´Â µ¥ ¼±±¸ÀûÀÎ ¿ªÇÒÀ» Çß½À´Ï´Ù.

Q ȯÀÚ Áø·á¿¡ ÀÖ¾î °¡Àå Áß¿äÇÏ°Ô »ý°¢ÇÏ´Â °¡Ä¡´Â?

±Ù°Å Á߽ɿ¡ ±â¹ÝÇÑ ÃÖ¼±ÀÇ Áø·á°¡ ¹«¾ùº¸´Ù Áß¿äÇÏÁö¸¸, ¸ö°ú ¸¶À½À» ÇÔ²² Ä¡·áÇØ¾ß ÇÑ´Ù°í »ý°¢ÇÕ´Ï´Ù.

Q ȯÀڵ鿡°Ô ÀüÇÏ°í ½ÍÀº ¸»¾¸

³úÁ¹Áß°ú Ä¡¸Å¿Í °°Àº ³úÁúȯÀº ¿¹¹æÀÌ ¹«¾ùº¸´Ù Áß¿äÇÕ´Ï´Ù. ³ú °Ç°­Àº ³ë·ÂÇϸé ÁÖ¾îÁö´Â ¼±¹°ÀÔ´Ï´Ù. ±ÝÁÖ, ±Ý¿¬°ú ÀûÀýÇÑ °íÇ÷¾Ð, ´ç´¢º´, ÀÌ»óÁöÇ÷ÁõÀÇ Á¶Àý°ú °°Àº ÀÏ»óÀûÀÎ ³ë·Â¿¡¼­ ¸ðµç °ÍÀÌ ½ÃÀ۵˴ϴÙ.

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

°¡Å縯´ëÇб³ ÀºÆò¼º¸ðº´¿ø

Á¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1811-7755
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

°¡Å縯´ëÇб³ ÀºÆò¼º¸ðº´¿øÀº 80¿© ³âÀÇ °¡Å縯 ÀÇ·á ¿ª·®À» ¹ÙÅÁÀ¸·Î, ÃÖ÷´Ü Àåºñ, ¾ÈÀüȯ ȯ°æ, ¿ì¼öÇÑ Áø·á ½Ã½ºÅÛÀ» °®Ãß°í ÀÖ½À´Ï´Ù. À̽Ä, ½ÉÀå, ¾Ï µî ÁßÁõ Áúȯ °í°´µé¿¡°Ô ¿ì¼öÇÑ ÀÇ·áÁøÀÌ ¼öÁØ ³ôÀº Ä¡·á¸¦ Á¦°øÇϸç, ÀÀ±ÞÀÇ·á¼¾ÅÍ¿Í ¼Ò¾ÆÀÀ±Þ½ÇÀ» ¿î¿µÇÏ¿© Áö¿ª»çȸÀÇ ÀÀ±Þ ȯÀڵ鿡°Ô ÇʼöÀûÀÎ ÀÇ·á ¼­ºñ½º¸¦ Áö¿øÇÕ´Ï´Ù. ¶ÇÇÑ, °¡Å縯 ÀÇ·á±â°üÀ¸·Î ÀÇ·á Ãë¾à°èÃþÀ» Áö¿øÇÏ´Â µîÀÇ »çȸ°øÇå Ȱµ¿À» Áö¼ÓÀûÀ¸·Î Àü°³Çϰí ÀÖ½À´Ï´Ù.

°¡Å縯´ëÇб³ ÀºÆò¼º¸ðº´¿ø 		 À̹ÌÁö

¼­¿ïƯº°½Ã ÀºÆò±¸ ÅëÀÏ·Î 1021

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä